Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure

Current biomarkers allow diagnosing a wide array of pathological processes and evaluating effects of therapies and prognosis for cardiological patients. This review focuses on a possibility of using N-terminal pro-brain natriuretic peptide (NT-proBNP), soluble suppressor of tumorigenicity 2 (sST2),...

Full description

Saved in:
Bibliographic Details
Published inKardiologiia Vol. 60; no. 4; p. 101
Main Authors Gasparyan, A Zh, Shlevkov, N B, Skvortsov, A A
Format Journal Article
LanguageRussian
Published Russia (Federation) 04.05.2020
Online AccessGet more information

Cover

More Information
Summary:Current biomarkers allow diagnosing a wide array of pathological processes and evaluating effects of therapies and prognosis for cardiological patients. This review focuses on a possibility of using N-terminal pro-brain natriuretic peptide (NT-proBNP), soluble suppressor of tumorigenicity 2 (sST2), galectin-3, and other biomarkers in patients with chronic heart failure for evaluating the risk of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
ISSN:0022-9040
DOI:10.18087/cardio.2020.4.n487